This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at http://www.bbc.co.uk/news/business-29274822

The article has changed 5 times. There is an RSS feed of changes available.

Version 2 Version 3
China fines GlaxoSmithKline $490m over bribery GlaxoSmithKline fined $490m by China for bribery
(35 minutes later)
China has fined UK pharmaceuticals firm GlaxoSmithKline $490m (£297m) after a court found it guilty of bribery.China has fined UK pharmaceuticals firm GlaxoSmithKline $490m (£297m) after a court found it guilty of bribery.
The record penalty follows allegations the drug giant paid out bribes to doctors and hospitals in order to have their products promoted.The record penalty follows allegations the drug giant paid out bribes to doctors and hospitals in order to have their products promoted.
GSK's former head of Chinese operations, Mark Reilly, has been given a three-year prison sentence - although it has been suspended for four years. The court gave GSK's former head of Chinese operations, Mark Reilly, a suspended three-year prison sentence and he is set to be deported.
Other GSK executives have also been given suspended jail sentences.Other GSK executives have also been given suspended jail sentences.
The guilty verdict was delivered after a one-day trial at a court in Changsha, according to the Xinhua news agency.The guilty verdict was delivered after a one-day trial at a court in Changsha, according to the Xinhua news agency.
Chinese authorities first announced they were investigating GSK in July last year, in what has become the biggest corruption scandal to hit a foreign firm in years. Chinese authorities first announced they were investigating GSK in July last year, in what has become the biggest corruption scandal to hit a foreign firm in years. The company was accused of having made an estimated $150m in illegal profits
GSK said it had "published a statement of apology to the Chinese government and its people".GSK said it had "published a statement of apology to the Chinese government and its people".
"Reaching a conclusion in the investigation of our Chinese business is important, but this has been a deeply disappointing matter for GSK," said chief executive Sir Andrew Witty in a statement."Reaching a conclusion in the investigation of our Chinese business is important, but this has been a deeply disappointing matter for GSK," said chief executive Sir Andrew Witty in a statement.
"We have and will continue to learn from this. GSK has been in China for close to a hundred years and we remain fully committed to the country and its people," he said."We have and will continue to learn from this. GSK has been in China for close to a hundred years and we remain fully committed to the country and its people," he said.
"We will also continue to invest directly in the country to support the government's health care reform agenda and long-term plans for economic growth.""We will also continue to invest directly in the country to support the government's health care reform agenda and long-term plans for economic growth."
Mick Cooper, analyst at Edison Investment Research in London, said: "GlaxoSmithKline will hope that this will draw a line under events in China, but it will take time for its Chinese commercial operations to recover."